A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees

被引:85
作者
Harland, M [1 ]
Mistry, S [1 ]
Bishop, DT [1 ]
Bishop, JAN [1 ]
机构
[1] St James Univ Hosp, ICRF Clin Ctr Leeds, Genet Epidemiol Div, Leeds LS9 7TF, W Yorkshire, England
关键词
D O I
10.1093/hmg/10.23.2679
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Germline mutations of CDKN2A at 9p21 have been shown to predispose to disease in melanoma pedigrees worldwide. However, there remains a significant proportion of melanoma pedigrees with evidence of linkage to 9p21 in which mutations in CDKN2A have not been detected. Investigation of other potential tumour suppressor genes at 9p21 and the promotor of CDKN2A has been unable to explain genetic predisposition to melanoma in these pedigrees. Here we describe a mutation, IVS2-105 A/G, deep in intron 2 of CDKN2A, detected in six English melanoma pedigrees. The mutation creates a false GT splice donor site 105 bases 5' of exon 3 and has been demonstrated to result in aberrant splicing of the mRNA. This is the most common mutation identified in English families to date. The presence of this deep intronic mutation in a relatively large number of kindreds, indicates that it may account for a significant proportion of 9p21-linked melanoma pedigrees with no detectable mutations in the coding region of CDKN2A. In addition, the identification of one deep intronic mutation in CDKN2A indicates the possibility of the existence of other similar splicing mutations located elsewhere in the CDKN2A introns.
引用
收藏
页码:2679 / 2686
页数:8
相关论文
共 45 条
[1]   ALTERNATIVE RNA PROCESSING IN CALCITONIN GENE-EXPRESSION GENERATES MESSENGER-RNAS ENCODING DIFFERENT POLYPEPTIDE PRODUCTS [J].
AMARA, SG ;
JONAS, V ;
ROSENFELD, MG ;
ONG, ES ;
EVANS, RM .
NATURE, 1982, 298 (5871) :240-244
[2]  
[Anonymous], 1987, Molecular Biology of the Gene
[3]  
Bishop DT, 2000, AM J HUM GENET, V67, P16
[4]   A point mutation in an intronic branch site results in aberrant splicing of COL5A1 and in Ehlers-Danlos syndrome type II in two British families [J].
Burrows, NP ;
Nicholls, AC ;
Richards, AJ ;
Luccarini, C ;
Harrison, JB ;
Yates, JRW ;
Pope, FM .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 63 (02) :390-398
[5]  
Dracopoli NC, 1996, CANCER SURV, V26, P115
[6]   Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds [J].
Flores, JF ;
Pollock, PM ;
Walker, GJ ;
Glendening, JM ;
Lin, AHT ;
Palmer, JM ;
Walters, MK ;
Hayward, NK ;
Fountain, JW .
ONCOGENE, 1997, 15 (24) :2999-3005
[7]   The CDKN2A (p16) gene and human cancer [J].
Foulkes, WD ;
Flanders, TY ;
Pollock, PM ;
Hayward, NK .
MOLECULAR MEDICINE, 1997, 3 (01) :5-20
[8]   Screening for CDKN2A mutations in hereditary melanoma [J].
Goldstein, AM ;
Tucker, MA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (10) :676-678
[9]  
Harland M, 2000, GENE CHROMOSOME CANC, V28, P45, DOI 10.1002/(SICI)1098-2264(200005)28:1<45::AID-GCC6>3.3.CO
[10]  
2-6